Use precise geolocation data and actively scan device characteristics for identification. This is done to store and access information on a device and to provide personalised ads and content, ad and ...

A successful claim for PIP or ADP is worth between £29.20 and £187.45 each week in additional financial support and as the ...

Inhaled corticosteroid (ICS) use was common among patients with bronchiectasis and was associated with reduced exacerbations ...

Pope Francis was suffering from a chronic lung condition, called multiple bronchiectasis ... with doctors often confusing it with asthma or other lung conditions. The number of cases has soared ...

Bronchiectasis impacts up to 500,000 Americans, but there is often misdiagnosis or delayed diagnosis as the condition can present similarly to other pulmonary conditions such as COPD or asthma. Senior ...

Bronchiectasis impacts up to 500,000 Americans, but there is often misdiagnosis or delayed diagnosis as the condition can present similarly to other pulmonary conditions such as COPD or asthma.

Neutrophils are the core airway inflammatory cell in bronchiectasis ... and 18.7% a history of asthma. Among the secondary endpoints, time to the first exacerbation was longer with brensocatib ...

were chronic obstructive pulmonary disease or asthma if the respiratory symptoms were primarily driven by these diseases (secondary diagnoses of these diseases were allowed); bronchiectasis due to ...

Amlitelimab reduced asthma exacerbations by over 70% in biomarker ... Finally, itepekimab is being explored in a phase 2 study in bronchiectasis, with the readout anticipated in 2026.

In asthma, amlitelimab shows potential as an ... in a phase 2 study (clinical study identifier: NCT06280391) in bronchiectasis, with the readout anticipated in 2026. About amlitelimab Amlitelimab ...